InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,586.86
(
-1.23%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Lewis R Goudy

Send PM Follow Ignore
Followers 4
Posts 624
Boards Moderated 0
Alias Born 10/10/2006

Lewis R Goudy

Re: None

Monday, 01/22/2007 11:40:35 AM

Monday, January 22, 2007 11:40:35 AM

Post# of 19309
"(Xigris) treatment in sepsis: a drug in trouble"

Drotrecogin alfa (activated) or recombinant human activated protein C (rhAPC) has been registered for use as adjuvant treatment in severe sepsis since 2001 under the trade name Xigris® essentially based on the results from one large clinical trial (the PROWESS trial). In a recently published second randomized clinical trial (the ADDRESS trial), enrolling patients with severe sepsis but with less risk of death, no effect of the treatment was shown, not even a trend to a positive effect in the subgroup of patients with a high risk of death that would match the present prescription label for Xigris®. In addition, a large randomized, placebo-controlled trial with rhAPC in paediatric sepsis has recently been terminated prematurely because of lack of efficacy. Altogether, the robustness of the data supporting the use of rhAPC in treating patients with severe sepsis may indeed be questioned. A confirmatory clinical trial is required before rhAPC can be used with confidence. The side-effects and the cost of rhAPC are well documented but its efficacy is not.

To cite this article: B. Gårdlund (2006)
Activated protein C (Xigris®) treatment in sepsis: a drug in trouble
Acta Anaesthesiologica Scandinavica 50 (8), 907–910.
doi:10.1111/j.1399-6576.2006.01086.x

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1399-6576.2006.01086.x?cookieSet=1&journalCod....

GTC longs ought be grateful to Lilly for having rendered such
yeoman service in paving the way for Atryn. They have put a
lot of money (by GTC standards) into raising the clinical profile
of sepsis (eg funding the Surviving Sepsis initiative). What
they have sown, may we reap.


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up